Improvement in Anxiety and Depression in Adult Patients with Severe Alopecia Areata Treated with Deuruxolitinib: Pooled Data from the THRIVE-AA1 and THRIVE-AA2 Phase 3 Trials

    September 2025 in “ Journal of the American Academy of Dermatology ”
    Arash Mostaghimi, Brett King, Maryanne M. Senna, Natasha Atanaskova Mesinkovska, Paradi Mirmirani, Colleen Hamilton, James V. Cassella
    TLDR Deuruxolitinib improves anxiety and depression in severe alopecia areata patients.
    The study pooled data from the THRIVE-AA1 and THRIVE-AA2 Phase 3 trials to evaluate the effects of deuruxolitinib on anxiety and depression in adult patients with severe alopecia areata. The results demonstrated significant improvements in both anxiety and depression symptoms among participants treated with deuruxolitinib. This suggests that deuruxolitinib not only addresses the physical symptoms of alopecia areata but also contributes positively to the mental health of patients suffering from this condition. The study highlights the potential of deuruxolitinib as a comprehensive treatment option for individuals with severe alopecia areata.
    Discuss this study in the Community →